Seeking Alpha

Oncothyreon -9.4% AH; tecemotide study fails to meet endpoints

  • Merck has informed Oncothyreon (NASDAQ:ONTY) a randomized Phase 1/2 study of its tecemotide immunotherapy in Japanese Stage III non-small cell lung cancer patients "did not meet its primary endpoint of an improvement in overall survival, and no treatment effect was seen in any of the secondary endpoints (progression free survival, time to progression or time to failure)."
  • Merck has advised Oncothyreon it will "recommend that the investigational treatment in the study be discontinued and that no recruitment of Japanese patients into the Phase 3 program of tecemotide will take place."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs